吉非替尼和多西他赛＋顺铂方案治疗老年晚期非小细胞肺癌的疗效比较

目的：观察吉非替尼和多西他赛＋顺铂方案治疗老年晚期非小细胞肺癌（NSCLC）的近期疗效和不良反应。方法：63例65岁以上老年晚期NSCLC患者,单用吉非替尼30例（试验组）,250 mg.d^-1;对照组33例,行多西他赛＋顺铂方案,多西他赛75 mg.（m2）^-1,第1天,顺铂75 mg.（m2）^-1,第1天。每3周为1个周期,两周期后评价客观疗效及不良反应。结果：两组总有效率试验组33.3%,对照组21.2%,P＞0.05;试验组疾病控制率试验组73.3%,对照组51.5%,P＜0.01。试验组的毒性反应主要为皮疹和腹泻,对照组的主要毒性为骨髓抑制和胃肠道反应,P＜0.05。试验组生活质量高于对照组,P＜0.05。结论：单药吉非替尼和多西他赛＋顺铂方案均可用于老年晚期非小细胞肺癌的治疗,但吉非替尼疾病控制率高,不良反应轻,耐受性好。

Efficacy of Gefitinib vs.Docetaxel plus Cisplatin for Advanced Non-small Cell Lung Cancer in Elderly Patients

OBJECTIVE： To evaluate the efficiency and toxicity of Gefitinib vs.Docetaxel plus Cisplatin for advanced for non-small cell lung cancer（NSCLC）in elderly patients.METHODS： 63 elderly patients with stage Ⅲ or stage Ⅳ NSCLC were enrolled： 30 cases（trial group）were assigned to recieve Oral Gefitinib 250mg daily,the other 33（control group）to receive Doccetaxe 75 mg·（m2）-1] on day 1 plus Cisplatin DDP,75 mg·（m2）-1] on day 1.Every three weeks（21 days）were defined as one cycle.The efficacy and adverse effects in the two groups were evaluated after two eyeles of treatments.RESULTS： The overall response rate was 33.3% in trial group vs. 21.2% in control group（ P 〉 0.05） . The relief rate of elinieal symptoms in trial group was 73.3% vs. 51,5% in control group（ P 〈 0.01 ）. Tile main toxieities in trial group appeared as skin rash and diarrhea while those in control group appeared as bone marrow depression and the alimentary tract reaction（ P 〈 0.05）. The score of quality of life in trial group was high than in control group（ P〈 0.05）. CONCLUSION： Either Gefitinib or Doeetaxel plus Cisplatin can be used for treatment of advanced NSCLC in elderly patients, but Gefitinib treatment showed higher disease control rate, milder toxicity and good tolerabilitvy